Researchers from Sanford Burnham Prebys Medical Discovery Institute (SBP) found that insulin responsiveness can be improved by blocking a cellular glucose sensor in muscle to prevent type 2 diabetes (T2D). Research findings with obesity-related diabetes show that MondoA protein is the main link between accumulation of fat (in muscle) and insulin resistance. The results show that MondoA protein causes accumulation and burning of fat in the muscle and acts as a gatekeeper. Type 2 diabetes (T2D) can be prevented by developing drugs to target MondoA protein. Dr. Daniel P Kelly was the key investigator of the study and research findings were published in the Journal of Clinical Investigation.
A study done by researchers from the Metformin Genetics Consortium shows that genetic variations were the key reason for the differences in results with metformin drug treatment. Researchers found that SLC2A2 gene was correlated with a strong response to metformin. Overweight people carrying two copies of SLC2A2 variant responds better with metformin drug. The results suggest that higher dosages of metformin are required for some diabetes patients to achieve good results. Dr. Kaixin Zhou, University of Dundee is the lead researcher of the study and the study findings were published in the online journal Nature.
Researchers from Aghia Sophia Children's Hospital, Athens Greece successfully invented and tested a method to diagnose and treat pediatric diabetic nephropathy kidney disease. Diabetic nephropathy was caused due to the damages to glomeruli in kidneys and the treatment option is dialysis. Currently increased urinary albumin excretion symptom was used to detect diabetic nephropathy disease. The disease development can be prevented if it was diagnosed before the increased kidney urinary albumin. Researchers say following proteins can be used to detect kidney related diabetic nephropathy disease before the increase in the urinary albumin excretion.
The new diagnosing method was presented during 68th AACC Annual Scientific Meeting & Clinical Lab Expo held in Philadelphia between 31st Jul and 4th Aug 2016.
A study done on kidney disease in the US shows that
Lead author of the study was Ian de Boer, Division of Nephrology (University of Washington) and the study findings were published in the journal of the American Medical Association (JAMA).
A study done by researchers from the US and Australia concluded that exercising for more than 12 hours (600 minutes) per week, 5 times higher to time suggested by WHO gives the best protection against chronic diseases like diabetes, breast cancer, bowel cancer, strokes and heart attacks. Currently, guidelines suggest individual should do moderate exercise (brisk walking or gardening) of at least 150 minutes per week or vigorous exercise (running or cycling) of at least 75 minutes per week. The study findings were published in the BMJ.
Researchers from the University of Helsinki, Finland led by Dr. Roope Tikkanen concluded that mutation in a gene of serotonin 2B receptor protein (also known as 5-Hydroxytryptamine receptor 2B, 5-HT2B) may result in lower BMI and higher insulin resistance. Researchers conducted a focused study on the aspects of insulin sensitivity, beta cell activity and body mass index (BMI) with individuals having an antisocial personality disorder. It is known fact that men with low testosterone levels are at more risk for metabolic disorders. But individuals with a mutation in a gene of serotonin 2B receptor protein and lower levels of testosterone leads to increases insulin sensitivity and lower BMI and better protected against type 2 diabetes (T2D). Research findings were published in the Journal of Psychiatric Research.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.